← ANALYST RATINGS · TIPRANKS
Faeth Therapeutics (FTH): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $56.60, the highest $70.00, the lowest $40.00. The average is +201.1% from the last price of $18.80.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $22.50 → $18.00−20.0% | Hold | −4.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $18.50−19.6% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $22.50 → $18.00−20.0% | Hold | −4.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $22.00 → $18.00−18.2% | Sell | −4.3% | Downgrade | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.00 → $18.50−19.6% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.00 → $18.00−18.2% | Sell | −4.3% | Downgrade | 17.10.26on TipRanks 05:06 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $55.00 | Buy | +192.6% | Reiterated | 15.10.26on TipRanks Oct 16 05:25 | +2.7%next day −7.6% | ↗ |
| Unknown Analyst | William Blair | $66.00 | Buy | +251.1% | Initiated | 15.10.26on TipRanks Oct 16 05:25 | +2.7%next day −7.6% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $40.00 | Buy | +112.8% | Initiated | 15.10.26on TipRanks 09:40 | +2.7%next day −7.6% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $60.00 | Buy | +219.1% | Reiterated | 21.09.26on TipRanks Sep 22 05:40 | −5.1%next day +0.3% · 5 days −15.6% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $70.00 | Buy | +272.3% | Initiated | 15.09.26on TipRanks 16:25 | −2.8%next day +1.5% · 5 days −9.9% | ↗ |
| Dev Prasad★★★★★★★★★★#663 · hits 80% · avg +91.6% | Lucid Capital | $59.00 | Buy | +213.8% | Initiated | 14.09.26on TipRanks 11:00 | +4.9%next day −9.1% · 5 days −16.7% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $55.00 | Buy | +192.6% | Reiterated | 13.09.26on TipRanks 21:20 | +4.9%next day −9.1% · 5 days −16.7% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Initiated | 09.09.26on TipRanks 05:50 | −7.4%next day +8.6% · 5 days −4.1% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $56.00 | Buy | +197.9% | Initiated | 21.08.26on TipRanks 05:55 | −0.7%next day +8.8% · 5 days +5.3% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $60.00 | Buy | +219.1% | Reiterated | 05.08.26on TipRanks 08:35 | −3.4%next day −0.3% · 5 days +19.1% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $55.00 | Buy | +192.6% | Initiated | 04.08.26on TipRanks 08:16 | −8.5%next day −3.4% · 5 days +17.7% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $56.00 | Buy | +197.9% | Initiated | 31.07.26on TipRanks 06:38 | −6.2%next day −1.1% · 5 days −14.0% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $51.00 | Buy | +171.3% | Initiated | 20.07.26on TipRanks 04:55 | +9.1%next day −0.2% · 5 days +4.1% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $57.00 | Buy | +203.2% | Initiated | 26.06.26on TipRanks Jun 25 16:25 | −6.6%next day −0.1% · 5 days +4.0% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | — | Buy | — | Reiterated | 03.06.26on TipRanks Jun 18 06:06 | −0.9%next day +4.4% · 5 days −24.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Faeth Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 6 | 11 | 15 | 14 | 11 |
| Buy | 0 | 0 | 0 | 0 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.78 (from $-1.86 to $-0.58). Last quarter: $-2.84.
Best top-analyst consensus in the sector · Healthcare
About Faeth Therapeutics
- CEO: Anand Parikh
- Employees: 29
- 1405 Research Blvd, Rockville, MD, 20850, US
- www.faeththerapeutics.com
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Data from the stock’s TipRanks forecast page, read 79 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗